<VariationArchive RecordType="classified" VariationID="934" VariationName="NM_000404.4(GLB1):c.256_278dup (p.Gln95fs)" VariationType="Duplication" Accession="VCV000000934" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-07-29" DateCreated="2021-05-07" MostRecentSubmission="2021-05-07">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="15973" VariationID="934">
      <GeneList>
        <Gene Symbol="GLB1" FullName="galactosidase beta 1" GeneID="2720" HGNC_ID="HGNC:4298" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="32961108" stop="33097146" display_start="32961108" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33038099" stop="33138693" display_start="33038099" display_stop="33138693" Strand="-" />
          </Location>
          <OMIM>611458</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000404.4(GLB1):c.256_278dup (p.Gln95fs)</Name>
      <CanonicalSPDI>NC_000003.12:33068937:GGCCAGGGCTCATGAAAGTTCCAGG:GGCCAGGGCTCATGAAAGTTCCAGGCCAGGGCTCATGAAAGTTCCAGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>3p22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33068937" stop="33068938" display_start="33068937" display_stop="33068938" variantLength="23" positionVCF="33068937" referenceAlleleVCF="T" alternateAlleleVCF="TGGCCAGGGCTCATGAAAGTTCCA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33110429" stop="33110430" display_start="33110429" display_stop="33110430" variantLength="23" positionVCF="33110429" referenceAlleleVCF="T" alternateAlleleVCF="TGGCCAGGGCTCATGAAAGTTCCA" />
      </Location>
      <ProteinChange>Q143fs</ProteinChange>
      <ProteinChange>Q65fs</ProteinChange>
      <ProteinChange>Q95fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.256_278dup" MANESelect="true">
            <Expression>NM_000404.4:c.256_278dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000395.3" sequenceAccession="NP_000395" sequenceVersion="3" change="p.Gln95fs">
            <Expression>NP_000395.3:p.Gln95fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079811.3" sequenceAccession="NM_001079811" sequenceVersion="3" change="c.166_188dup">
            <Expression>NM_001079811.3:c.166_188dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073279.2" sequenceAccession="NP_001073279" sequenceVersion="2" change="p.Gln65fs">
            <Expression>NP_001073279.2:p.Gln65fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317040.2" sequenceAccession="NM_001317040" sequenceVersion="2" change="c.400_422dup">
            <Expression>NM_001317040.2:c.400_422dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001303969.2" sequenceAccession="NP_001303969" sequenceVersion="2" change="p.Gln143fs">
            <Expression>NP_001303969.2:p.Gln143fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001393580.1" sequenceAccession="NM_001393580" sequenceVersion="1" change="c.256_278dup">
            <Expression>NM_001393580.1:c.256_278dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001380509.1" sequenceAccession="NP_001380509" sequenceVersion="1" change="p.Gln95fs">
            <Expression>NP_001380509.1:p.Gln95fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001135602.3" sequenceAccession="NM_001135602" sequenceVersion="3" change="c.246-3403_246-3381dup">
            <Expression>NM_001135602.3:c.246-3403_246-3381dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.33110432_33110454dup" Assembly="GRCh37">
            <Expression>NC_000003.11:g.33110432_33110454dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.33068940_33068962dup" Assembly="GRCh38">
            <Expression>NC_000003.12:g.33068940_33068962dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009005.1" sequenceAccession="NG_009005" sequenceVersion="1" change="g.33243_33265dup">
            <Expression>NG_009005.1:g.33243_33265dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA114648" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="611458.0012" DB="OMIM" />
        <XRef Type="rs" ID="587776524" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 1606711 Fig. 2 to determine the location of this allele on the current reference sequence.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000404.4(GLB1):c.256_278dup (p.Gln95fs) AND Infantile GM1 gangliosidosis" Accession="RCV000000983" Version="3">
        <ClassifiedConditionList TraitSetID="244">
          <ClassifiedCondition DB="MedGen" ID="C0268271">Infantile GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1992-05-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1992-05-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-07" MostRecentSubmission="2021-05-07">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1606711</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1907800</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="244" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5204" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Infantile GM1 gangliosidosis</ElementValue>
                <XRef ID="Infantile+GM1+gangliosidosis/8659" DB="Genetic Alliance" />
                <XRef ID="238026007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-gangliosidosis, type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, infantile form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1 gangliosidosis type 1</ElementValue>
                <XRef ID="MONDO:0009260" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 1</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6479" />
                <XRef ID="6479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79255" DB="Orphanet" />
              <XRef ID="C0268271" DB="MedGen" />
              <XRef ID="MONDO:0009260" DB="MONDO" />
              <XRef Type="MIM" ID="230500" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="21133" SubmissionDate="2021-05-04" DateLastUpdated="2021-05-07" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="611458.0012_GM1-GANGLIOSIDOSIS, TYPE I" title="GLB1, 23-BP DUP_GM1-GANGLIOSIDOSIS, TYPE I" />
        <ClinVarAccession Accession="SCV000021133" DateUpdated="2021-05-07" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1992-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a 5-year-old boy with the infantile form of GM1-gangliosidosis (GM1G1; 230500), Oshima et al. (1992) found compound heterozygosity for 2 mutations in the GLB1 gene: a 23-bp duplication in exon 3 and Y316C (611458.0007). The duplication resulted in a premature stop codon after translation of 36 amino acids. Homologous sequences in the area of duplication suggested that the mutation resulted from an unequal crossover. The boy had hepatomegaly and liver dysfunction at 6 months of age. Cherry-red spots were found bilaterally at the age of 1 year and the diagnosis of GM1-gangliosidosis was made. He deteriorated to a state of decerebrate rigidity by the age of 5 years. The patient had previously been reported by Yoshida et al. (1991).</Attribute>
              <Citation>
                <ID Source="PubMed">1606711</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">1907800</ID>
              </Citation>
              <XRef DB="OMIM" ID="230500" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <Name>GLB1, 23-BP DUP</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">23-BP DUP</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="611458.0012" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GM1-GANGLIOSIDOSIS, TYPE I</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="21133" TraitType="Disease" MappingType="Name" MappingValue="GM1-GANGLIOSIDOSIS, TYPE I" MappingRef="Preferred">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

